期刊文献+

噻托溴胺治疗慢性阻塞性肺疾病80例临床观察 被引量:1

Clinical Observation on Tiotropium Treatment of 80 Cases of Chronic Obstructive Pulmonary Disease
下载PDF
导出
摘要 目的观察噻托溴胺治疗慢性阻塞性肺疾病(COPD)的临床疗效,并探讨其可能的作用机制。方法选取2011年3月至2012年12月在济南市第四人民医院呼吸科就诊的稳定性COPDⅢ~Ⅳ级患者160例,按随机数字表法分为两组:噻托溴铵组(80例)给予噻托溴胺吸入治疗,氨茶碱控释片组(80例)给予氨茶碱控释片(0.1 g口服,每日3次)治疗。比较两组患者治疗前后心功能变化及不良反应情况。结果噻托溴铵组总有效为92.50%,氨茶碱控释片组为78.75%,差异有统计学意义(P〈0.05);噻托溴铵组不良反应发生率为3.75%,氨茶碱控释片组为13.75%,差异有统计学意义(P〈0.05)。结论噻托溴胺治疗COPD较氨茶碱疗效较好,维持时间长,不良反应较少,可提高慢阻肺患者生活质量。 Objective To observe the clinical effect of tiotropium bromide in the treatment of chronic obstructive pulmonary disease( COPD),and to explore the potential mechanism of action.Methods A total of 160 stable COPD Ⅲ-Ⅳ patients in Department of Respiratory of the Fourth People's Hospital of Jinan City from Mar. 2011 to Dec. 2012 were included in the study,and were randomly divided into tiotropium bromide group and release-controlled aminophylline group,80 cases each: the former group received tiotropium bromide inhalation therapy,the latter group was given release aminophylline tablets( 0. 1 g PO,3 times / day). The heart function and adverse reactions of the two groups before and after treatment were compared. Results Curative effect: 92. 50% in the tiotropium bromide group,78. 75% in the release-controlled aminophylline group,the difference was statistically significant( P〈0. 05); adverse reaction rate of the tiotropium bromide group was 3. 75%,of the releasecontrolled aminophylline group was 13. 75%,the difference was statistically significant( P〈0. 05).Conclusion The effect of tiotropium bromide is better than aminophylline for COPD,with longer effective time and less adverse reactions,which as a result improves the quality of life of COPD patients.
出处 《医学综述》 2015年第3期575-576,共2页 Medical Recapitulate
关键词 慢性阻塞性肺疾病 噻托溴铵 临床疗效 Chronic obstructive pulmonary disease Tiotropium bromide Clinical effect
  • 相关文献

参考文献7

二级参考文献38

  • 1有创-无创序贯机械通气多中心研究协作组.以肺部感染控制窗为切换点行有创与无创序贯机械通气治疗慢性阻塞性肺疾病所致严重呼吸衰竭的随机对照研究[J].中华结核和呼吸杂志,2006,29(1):14-18. 被引量:279
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8235
  • 3张明同.精神科评定量表手册.长沙:湖南科学技术出版社,1993:162-165.
  • 4Diederen BM, van der Valk PD, Kluytmans JA, et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease [J]. Eur Respir J, 2007,30(2):240-244.
  • 5Fan P, Dong F, Huang Y, et al. Chlamydia pneumoniae secrection of a proteases-like activity factor for degrading host cell transcription factor required for major histocompatibility complex antigen expres- sion[J]. Infection Immunity, 2002, 70(1):345-349.
  • 6Weis N, Almdal T. C-reactive protein--can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmo- nary disease? [J]. Eur J Intern Med,2006,17(2) :88-91.
  • 7Brand6n E, Koyi H, Gnarpe J, et al. Intermittent azithromy- cin treatment for respiratory symptoms in patients with chro- nic Chlamydia pneumoniae infection[J]. Scand J Infect Dis, 2004, 36(11-12) :811-816.
  • 8Miyashita N. Chlamydia pneumoniae infections[J]. Kekaku, 2006,81(9) :581-588.
  • 9granden E, Koyi H, Gnarpe J, et al. Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD[J]. Respir Med, 2005, 99(1) :20-26.
  • 10Mauskopf JA, Baker CL, Monz BU, et al. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence[J]. J Med Econ, 2010, 13(3) :403-417.

共引文献8281

同被引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部